Role of the CXCR6/CXCL16 axis in autoimmune diseases
International Immunopharmacology · 2023-08 · 121 · 110530
DOI: 10.1016/j.intimp.2023.110530 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023-08. Verfasst von Nandi Bao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Cardiology, The Sixth Medical Center, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Chemokines, CXC, Autoimmune Diseases. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 157 Literaturangaben. Gefördert von: Chinese PLA General Hospital.
Abstract (Originalsprache)
The C-X-C motif ligand 16, or CXCL16, is a chemokine that belongs to the ELR - CXC subfamily. Its function is to bind to the chemokine receptor CXCR6, which is a G protein-coupled receptor with 7 transmembrane domains. The CXCR6/CXCL16 axis has been linked to the development of numerous autoimmune diseases and is connected to clinical parameters that reflect disease severity, activity, and prognosis in conditions such as multiple sclerosis, autoimmune hepatitis, rheumatoid arthritis, Crohn's disease, and psoriasis. CXCL16 is expressed in various immune cells, such as dendritic cells, monocytes, macrophages, and B cells. During autoimmune diseases, CXCL16 can facilitate the adhesion of immune cells like monocytes, T cells, NKT cells, and others to endothelial cells and dendritic cells. Additionally, sCXCL16 can regulate the migration of CXCR6-expressing leukocytes, which includes CD8+ T cells, CD4+ T cells, NK cells, constant natural killer T cells, plasma cells, and monocytes. Further investigation is required to comprehend the intricate interactions between chemokines and the pathogenesis of autoimmune diseases. It remains to be seen whether the CXCR6/CXCL16 axis represents a new target for the treatment of these conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Senior Department of Cardiology, The Sixth Medical Center, Chinese PLA General Hospital, Beijing, China.
- Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Beijing, China; State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, China.
- Department of neurology, School of Medicine, South China University of Technology, Guangzhou, China; Department of neurology, The Sixth Medical Center of PLA General Hospital of Beijing, Beijing, China.
- Department of neurology, The Sixth Medical Center of PLA General Hospital of Beijing, Beijing, China; Navy Clinical College, the Fifth School of Clinical Medicine, Anhui Medical University, Hefei, China.
- Navy Clinical College, the Fifth School of Clinical Medicine, Anhui Medical University, Hefei, China.
- Department of Gastroenterology, The Second Medical Center, Chinese PLA General Hospital, Beijing, China; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.
Förderung
- Chinese PLA General Hospital
Zitieren
APA
Bao, N., Fu, B., Zhong, X., Jia, S., Ren, Z., Wang, H., Wang, W., Shi, H., Li, J., Ge, F., Chang, Q., Gong, Y., Liu, W., Qiu, F., Xu, S., & Li, T. (2023). Role of the CXCR6/CXCL16 axis in autoimmune diseases. International Immunopharmacology, 121, 110530. https://doi.org/10.1016/j.intimp.2023.110530
Vancouver
Bao N, Fu B, Zhong X, Jia S, Ren Z, Wang H, et al. Role of the CXCR6/CXCL16 axis in autoimmune diseases. International Immunopharmacology. 2023;121:110530. doi:10.1016/j.intimp.2023.110530
BibTeX
@article{Bao2023,
author = {Bao, Nandi and Fu, Bo and Zhong, Xiaoling and Jia, Shuangshuang and Ren, Zhuangzhuang and Wang, Haoran and Wang, Weihua and Shi, Hui and Li, Jun and Ge, Fulin and Chang, Qing and Gong, Yuan and Liu, Wenhui and Qiu, Feng and Xu, Shiping and Li, Tingting},
title = {Role of the CXCR6/CXCL16 axis in autoimmune diseases},
journal = {International Immunopharmacology},
year = {2023},
volume = {121},
pages = {110530},
doi = {10.1016/j.intimp.2023.110530}
}
EUVIMED